Merck is bracing for lower first-quarter Gardasil sales due to weak demand in China and Japan, compounded by a temporary shipment halt to its Chinese partner Zhifei. While other legacy vaccines also ...
Zacks Investment Research on MSN
Will lower Gardasil sales hurt MRK's vaccines sales in Q1 earnings?
Merck MRK continues to encounter persistent challenges with its second-largest product, Gardasil, a vaccine approved to ...
(Reuters) -Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.
Beginning in September 2012, the UK’s National Health System will replace Ceverex, produced by GlaxoSmithKline(NYSE:GSK), with Gardasil from Merck (NYSE: MRK) for its HPV vaccine program, the health ...
The U.S. now only recommends one dose of an HPV vaccine. It used to say all children should get two to three doses of the vaccine, depending on their age. The U.S. now recommends that children get ...
Despite indications that a single dose of Merck's (NYSE:MRK) human papillomavirus vaccine Gardasil could be as effective as the current multi-dosing schedule, the drugmaker said that an alternative ...
(Reuters) -One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck’s Gardasil vaccine, ...
Over that period, 10.3% of women developed a new HPV infection. Incidence was highest among women ages 27 to 29, with a ...
HPV vaccine will include boys when it rolls out in Kenya in September, a move that could significantly improve future cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results